Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

With insomnia, the figures are staggering: nearly one-third of Americans experience some level of sleep disruption, and for ...

A new study indicates that the drug suvorexant could reduce proteins associated with Alzheimer's by improving sleep quality.

Eisai has launched its insomnia drug Dayvigo in Japan ... Dayvigo (lemborexant) is a dual orexin 1 and 2 receptor antagonist (DORA), a class which is billed as having fewer “morning-after ...

But the study of adolescents in the US also showed that even ... Insomnia and Sleep Medication Use Connected to Disability in Older Adults Apr. 18, 2025 — For adults over the age of 65 ...

More symptoms of insomnia and greater use of sleep medication are linked to a higher risk of disability a year later in older adults. The corresponding study was published in Sleep. Evidence suggests ...

Sleep medication usage showed a similar pattern — each additional level of reported use (from “never” to “every night”) was associated with approximately a 20% increase in disability risk.

“We found that as older people used more sleep medication or experienced more insomnia symptoms, they moved more rapidly toward greater disability,” said study co-author Orfeu ...

This study investigated the ... Adolescents who sleep for longer—and from an earlier bedtime—than their peers tend to have improved brain function and perform better at cognitive tests ...

CINCINNATI (WKRC) - A commonly prescribed sleeping pill could be a powerful ... were very short-lived and that regularly taking the medication came with a slew of other side effects.